Swedish Orphan Biovitrum (Sobi) has agreed to buy the drug emapalumab from Novimmune for $519 million per the terms of a licensing agreement signed in 2018. The deal includes the staff involved with the drugs development as well as a priority review voucher from the U.S. FDA. This comes as Sobi has announced that it is reorganizing to increase its focus on late-stage development in hematology and immunology, resulting in the elimination of roughly 90 jobs in R&D. Moving forward Sobi’s R&D efforts will be split between Sweden and Switzerland, the latter being home to Novimmune. Learn More